It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANRO’s FA Score shows that 1 FA rating(s) are green whileNRXS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANRO’s TA Score shows that 6 TA indicator(s) are bullish while NRXS’s TA Score has 3 bullish TA indicator(s).
ANRO (@Biotechnology) experienced а +6.90% price change this week, while NRXS (@Biotechnology) price change was -3.91% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.
ANRO is expected to report earnings on Aug 19, 2026.
NRXS is expected to report earnings on Sep 17, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ANRO | NRXS | ANRO / NRXS | |
| Capitalization | 984M | 85.2M | 1,155% |
| EBITDA | -71.22M | -7.12M | 1,001% |
| Gain YTD | 57.472 | 51.542 | 112% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 4.28M | - |
| Total Cash | 264M | 7.08M | 3,729% |
| Total Debt | 23.2M | 354K | 6,554% |
| ANRO | NRXS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | N/A |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 84% |
| Advances ODDS (%) | 5 days ago 89% | 18 days ago 86% |
| Declines ODDS (%) | 12 days ago 85% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 79% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| TIEUX | 17.00 | N/A | N/A |
| Morgan Stanley Pathway Intl Eq | |||
| HIGCX | 19.68 | N/A | N/A |
| Carillon Eagle Growth & Income C | |||
| ENHRX | 11.11 | N/A | N/A |
| Cullen Enhanced Equity Income Retail | |||
| FBCIX | 82.43 | -0.18 | -0.22% |
| American Funds Capital Inc Bldr 529-F-2 | |||
| DUSLX | 46.53 | -0.53 | -1.13% |
| DFA US Large Cap Growth Instl | |||
A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with NERV. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then NERV could also see price increases.
| Ticker / NAME | Correlation To ANRO | 1D Price Change % | ||
|---|---|---|---|---|
| ANRO | 100% | +5.85% | ||
| NERV - ANRO | 40% Loosely correlated | -9.53% | ||
| NUVL - ANRO | 38% Loosely correlated | +0.03% | ||
| OMER - ANRO | 38% Loosely correlated | -2.63% | ||
| PRAX - ANRO | 38% Loosely correlated | -3.21% | ||
| IMTX - ANRO | 37% Loosely correlated | -4.65% | ||
More | ||||
A.I.dvisor indicates that over the last year, NRXS has been loosely correlated with CVM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NRXS jumps, then CVM could also see price increases.
| Ticker / NAME | Correlation To NRXS | 1D Price Change % | ||
|---|---|---|---|---|
| NRXS | 100% | -3.64% | ||
| CVM - NRXS | 58% Loosely correlated | -11.59% | ||
| ANRO - NRXS | 28% Poorly correlated | +5.85% | ||
| PVLA - NRXS | 28% Poorly correlated | +0.88% | ||
| RANI - NRXS | 25% Poorly correlated | -7.95% | ||
| CTMX - NRXS | 25% Poorly correlated | -1.60% | ||
More | ||||